Other · developed by TAKEDA PHARMACEUTICAL CO
TAK-928 is an agent administered by intravenous infusion. It is being studied in immuno-oncology (IO)-resistant squamous and nonsquamous non-small cell lung cancer (NSCLC).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07217301 | Phase 3 | IO Resistant Squamous and Nonsquamous NSCLC | Recruiting | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
IO Resistant Squamous and Nonsquamous NSCLC
Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →